Company profile
RENOVORX, INC.
NASDAQ:RNXTBiotechnology: Pharmaceutical Preparations
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02237157 | phase1 | completed | 2015-03-01 | 2016-09-01 | RenovoRx | A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer |
| NCT03257033 | phase3 | active_not_recruiting | 2018-03-12 | 2027-06-01 | RenovoRx | Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC |
FDA applications (0)
No records yet.